Diabetes CKD Lifestyle Technology Study

NCT02266823 | Completed

• 1 other identifier: 14-00563
• Study Type: interventional
• Target: 270
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to pilot test an mHealth technology-supported behavioral intervention designed to engage patients with diabetes and concurrent chronic kidney disease (CKD) in multiple behaviors which aim to reduce CKD progression. Participants will be randomized to the 6-month lifestyle intervention or to a wait-list control. The lifestyle intervention will be modeled after that used in the Diabetes Prevention Program (DPP) and the counseling intervention will be based on SCT, which will be paired with mobile technology-based dietary and physical activity monitoring. The wait-list control will receive 6 months of standard medical care followed by a delayed, but less intensive, 6-month intervention.

Conditions

Chronic Kidney Disease; Diabetes; Obesity

Outcome Measures

Primary Outcomes (14)

• Primary outcome: Weight. Weight will be obtained using a single, calibrated scale.

  Change from baseline in weight at 6 months

• Primary outcome: Urinary sodium. We will estimate dietary sodium intake from a spot urine sample.

  Change from baseline in Urinary sodium at 6 months

• Primary outcome: Blood pressure. BP will be obtained using a mercury sphygmomanometer

  Change from baseline in Blood pressure at 6 months

• Primary outcome: Physical activity. Energy expenditures and minutes devoted to physical activity will be recorded using a FitBit.

  Change from baseline in Physical activity at 6 months

• Primary outcome: Serum Cystatin-C. Cystatin-C is a serum protein that is used as a biomarker of kidney function

  Change from baseline in Cystatin-C at 6 months

• Primary outcome: Lipoproteins. We will evaluate the impact of the intervention on serum lipids obtained after a 12-hour fast

  Change from baseline in Lipoproteins at 6 months

• Primary outcome: Serum Phosphorus and corrected Calcium-Phosphorus product (CaxPO4) will be evaluated from a venipuncture sample.

  Corrected CaxPO4 is a measure of metastatic calcification, adjusted for the participant's nutritional status (serum albumin). When serum albumin is \< 4 g/dL, the algorithm for corrected CaxPO4 is \[Ca + 0.8(4 - serum albumin)\]x PO4. When serum albumin if \> 4 g/dL, corrected CaxPO4 = CaxPO4. CaxPO4 is obtained with routine monthly labs on all HD patients

  Change from baseline in Serum Phosphorus and corrected Calcium-Phosphorus product at 6 months

• Primary outcome: Serum Phosphorus and corrected Calcium-Phosphorus product (CaxPO4) will be evaluated from a venipuncture sample.

  Corrected CaxPO4 is a measure of metastatic calcification, adjusted for the participant's nutritional status (serum albumin). When serum albumin is \< 4 g/dL, the algorithm for corrected CaxPO4 is \[Ca + 0.8(4 - serum albumin)\]x PO4. When serum albumin if \> 4 g/dL, corrected CaxPO4 = CaxPO4. CaxPO4 is obtained with routine monthly labs on all HD patients

  Change from baseline in Serum Phosphorus and corrected Calcium-Phosphorus product at 12 months

• Primary outcome: Weight. Weight will be obtained using a single, calibrated scale.

  Change from baseline in weight at 12 months

• Primary outcome: Urinary sodium. We will estimate dietary sodium intake from a spot urine sample.

  Change from baseline in Urinary sodium at 12 months

• Primary outcome: Blood pressure. BP will be obtained using a mercury sphygmomanometer

  Change from baseline in Blood pressure at 12 months

• Primary outcome: Physical activity. Energy expenditures and minutes devoted to physical activity will be recorded using a FitBit.

  Change from baseline in Physical activity at 12 months

• Primary outcome: Serum Cystatin-C. Cystatin-C is a serum protein that is used as a biomarker of kidney function

  Change from baseline in Cystatin-C at 12 months

• Primary outcome: Lipoproteins. We will evaluate the impact of the intervention on serum lipids obtained after a 12-hour fast

  Change from baseline in Lipoproteins at 12 months

Study Arms (2)

Intervention: Lifestyle A.

ACTIVE COMPARATOR

Lifestyle A will receive an iPad loaded with a self-monitoring program used to support vigilance, reduce the information processing requirements, make readily available the information required to make good self-management decisions, provide real-time feedback, and permit targeted counseling in the context within which lifestyle behaviors occur. Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling.

Behavioral: Social Cognitive Theory

Intervention: Lifestyle B.

OTHER

Participants randomized to this group will receive 6 months of routine care followed by a delayed intervention. Lifestyle B will employ the same diet and physical activity prescription as Lifestyle A as described above. Using Social Cognitive Theory, the study dietitian will counsel participants via videoconferencing software on the iPad. Using the detailed nutritional and physical activity feedback from the self monitoring programs, the dietitian will use SCT to engage the participants in order to initiate healthy behavior change whilst reducing the demands of commuting for in person nutritional counseling.

Behavioral: Social Cognitive Theory

Interventions

Social Cognitive Theory BEHAVIORAL

The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.

Also known as: SCT

Intervention: Lifestyle A.; Intervention: Lifestyle B.

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• In order to be eligible for the study, the individual must be 40 years of age or older; have a DRG Code of T2DM, GFR of 15-89 ml/min/1.73m2 and a BMI \>30 kg/m2. The participant's physician of record will have verified that his/her patient can safely participant in an intervention study that involves weight loss and a goal of 150 minutes/week of moderate physical activity (comparable to brisk walking).

You may not qualify if:

• Those with the following characteristics will be excluded by the investigators:
• unable or unwilling to provide informed consent; (2) unable to participate meaningfully in an intervention that involves group sessions (e.g., due to uncorrected hearing impairment, non-English-speaking); (3) unable to read or otherwise use an iPad to monitor dietary intake, physical activity, and weight (e.g., blind, illiterate); (4) unwilling to accept randomization assignment; (5) pregnant, or plans to become pregnant in the next 12 months, less than 3 months postpartum, or nursing or within 6 weeks of having completed nursing; (6) weight loss of \> 10% in the past 6 months except for postpartum weight loss; and (7) individuals who are institutionalized (e.g., in a nursing home or personal care facility, or those who are incarcerated and have no control over their diet).
• will exclude from the study those with underlying diseases which would increase the risk of participating in an intervention involving caloric restriction and physical activity. Such individuals would include those requiring treatment for cancer, exclusive of skin cancer other than melanoma, in the past 2 years; infectious diseases including untreated AIDS and active tuberculosis; uncontrolled hypertension of \>190 mmHg SBP or \>105 mmHg DBP despite treatment; stroke or TIA in the past 6 months; conditions requiring the use of home oxygen; or other chronic disease or condition likely to limit life span to \< 1 year. A recent Institute of Medicine report suggests that reducing dietary sodium below 1,840 mg/day in those with mid- to late-stage heart failure may increase adverse events or mortality. Thus investigators will exclude those with heart failure.

Sponsors & Collaborators

• NYU Langone Health: lead

Study Sites (1)

NYU Langone Medical Center

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Renal Insufficiency, Chronic; Diabetes Mellitus; Obesity

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms

Study Officials

• Mary Ann Sevick, ScD, RN

  NYU School of Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 18, 2014
• First Posted: October 17, 2014
• Study Start: October 1, 2015
• Primary Completion: November 8, 2019
• Study Completion: November 8, 2019
• Last Updated: January 22, 2020

Record last verified: 2020-01

Locations

US (1)